Sarepta Therapeutics reports 73 percent slowing of Duchenne muscular dystrophy progression in long term study

Sarepta Therapeutics SRPTreleased three-year clinical data from a late-stage study on January 26, 2026, demonstrating that its Elevidys gene therapy achieved a 73 percent slowing of disease progression in patients with Duchenne muscular dystrophy. The study compared treated participants to an external control group, measuring efficacy through the time required for patients to rise from the floor. This trial specifically enrolled participants who were aged 4 to 7 at the time of treatment and were still able to walk.